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ABSTRACT
We describe a series of women after allogeneic stem cell transplantation with vaginal graft-versus-host disease
(GVHD) who were treated with topical cyclosporine, surgery, or both. We reviewed the medical charts of 11
women who presented with vaginal pain, discomfort, and vaginal scarring (inability to perform a Papanicolaou
test or have vaginal intercourse because of pain). Vaginal symptoms develop an average of 10 months from
bone marrow transplantation. Symptoms and physical findings include excoriated and ulcerated mucosa,
thickened mucosa, narrowed introitus, and obliterated introitus from dense scar tissue that does not re-
solve with systemic or topical estrogens. The severity of symptoms and the physical findings in our study
population did not correlate with age, type of leukemia, type of transplant, or severity or acute or chronic
GVHD. Excoriated mucosa and moderately thickened mucosa were successfully treated with topical cyclo-
sporine. Extensive synechiae and complete obliteration of the vaginal canal required surgical lysis with
postoperative topical cyclosporine. Vaginal GVHD can successfully be treated with topical cyclosporine when
mild to moderate disease is present. Surgical lysis with topical cyclosporine is required when more severe
disease ensues.
© 2003 American Society for Blood and Marrow Transplantation
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Hematopoietic stem cell transplantation (HSCT)
s frequently performed to treat disorders of the blood
nd immune system. It is often complicated by graft-
ersus-host disease (GVHD). The pathogenesis of
oth acute and chronic GVHD is believed to be a
omplex immune response, primarily T-cell mediated,
n which the grafted donor cells recognize the host as
oreign. The effects of this condition are well de-
cribed involving the skin, gastrointestinal tract, lung,
nd liver [1-3].
After an HSCT, women frequently present with
ulvar or vaginal complaints of dryness, irritation,
yspareunia, and postcoital bleeding. These symp-
oms are generally attributed to lack of adequate es-
rogenization of the vulvar and vaginal mucosa, be-
ause most women experience premature ovarian
ailure secondary to the transplant conditioning regi-
en. There is increasing evidence in the literature p
60hat this vulvar/vaginal symptomatology may be due,
t least in part, to GVHD [5-10]. We present a series
f women after HSCT with these symptoms who did
ot respond to topical and systemic estrogen therapy
nd who were believed to have GVHD of the vulva
nd vagina. These women were treated with topical
mmunosuppressive therapy and vaginal dilators, and
ome required surgery. This is the ﬁrst series of pa-
ients in whom topical immunosuppressive agents
ere used in the treatment of genital GVHD.
ATERIALS AND METHODS
Medical charts of 11 women’s status after bone
arrow transplantation with vaginal symptoms that
ere not responding to estrogen therapy (Table 1)
ere reviewed. Approval was obtained from the insti-
utional review board of Brigham and Women’s Hos-oi:10.1016/j.bbmt.2003.08.001a
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ital. Conditioning regimens used in the study popu-
lation included cyclophosphamide plus total body
irradiation (14 Gy) or busulfan/cyclophosphamide. All
transplant recipients received bone marrow as the
source of stem cells. GVHD prophylaxis was systemic
cyclosporine and methotrexate or tacrolimus and
methotrexate administered according to standard
schedules. Chronic GVHD was also treated with sys-
temic cyclosporine and steroids with standard tapers
once symptoms had abated.
All women were initiated on hormone-replace-
ment regimens at the time of transplantation for treat-
ment prophylaxis for ovarian failure. Women who had
persistent vaginal pain, discomfort, vaginal scarring
(inability to perform a Papanicolaou test or have vag-
inal intercourse because of pain), or postcoital bleed-
ing were referred to one of the authors of this study.
All referred patients were included in our study pop-
ulation and had physical ﬁndings not consistent with a
hypoestrogenic vulva or vagina.
Cyclosporine vaginal cream was compounded by
using 200 mg of the oral suspension of cyclosporine
with evaporation of the alcohol and placed in a vehicle
of 5 g of an anhydrous ointment base. Cyclosporine
vaginal cream was compounded because at the time of
initial evaluation of these patients, topical tacrolimus
was not commercially available. The standard regimen
for cyclosporine cream in our patient population was
application 2 times a day for 4 weeks, followed by a
taper over the next 2 months. Flares of vulvar and
vaginal symptoms were treated in a similar manner.
RESULTS
Tables 1 to 3 summarize the data from our series.
The women ranged in age from 25 to 59 years at the
time of leukemia diagnosis and HSCT. All patients in
this series received high-dose cyclophosphamide and
total body irradiation as a conditioning regimen be-
fore transplantation. Five women underwent a sibling-
matched transplantation, and 6 received a matched
unrelated donor transplant. After the transplantation,
Table 1. Severity of GVHD
Subject
No. Leukemia
Age at
HSCT Type of HSCT
Severity of
Acute GVHD
Severity of Chronic
GVHD
Severity of Vulva/Vaginal
Physical Findings
1 Myelodysplastic
syndrome
34 Matched related Mild Mild to moderate Moderate
2 AML 25 Matched unrelated None None Severe
3 CLL 44 Matched unrelated Mild Severe Severe
4 CML 47 Matched unrelated Moderate Mild Moderate
5 CML 54 Matched related Moderate Severe Moderate
6 Myelodysplastic
syndrome/AML
37 Matched related Mild Mild Severe
7 AML 51 Matched related Mild None Severe
8 ALL/AML 25/27 Matched unrelated 1 mild, 2 none Mild to moderate Moderate
9 Lymphocytic
leukemia
28 Matched related Moderate Mild Mild
10 AML 23/26 Matched unrelated 1 none, 2 none 1 mild, 2 moderate Moderate
11 CLL 59 Matched unrelated Mild Moderate Severe
AML indicates acute myeloid leukemic; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; ALL, acute lymphocytic
leukemia.
Table 2. Treatment Regimens for Vaginal and Vulva GVHD
Subject
No.
Time from HSCT to Development
of Vaginal Symptoms Systemic Estrogens Topical Estrogens
Preoperative Topical
Cyclosporine Surgery
1 5 mo Yes Yes Yes Yes
2 3 mo Yes No No Yes
3 6 mo Yes Yes Yes Yes
4 14 mo Yes Yes Yes No
5 5 mo Yes Yes Yes No
6 13 mo Yes No Yes Yes
7 24 mo Yes No No Yes
8 8 mo from No. 2 Yes No Yes Yes
9 9 mo Yes No Yes* No
10 18 mo from No. 2 Yes Yes Yes No
11 8 mo Yes Yes Yes Yes
*Tacrolimus.
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all women were maintained on a short course of sys-
temic cyclosporine GVHD prophylaxis. Additionally,
these women were placed on either estrogen 0.625
mg/progesterone 2.5 mg or estrogen 0.625 mg/meth-
yltestosterone 1.25 mg with progesterone 2.5 mg each
day as hormone replacement therapy for ovarian fail-
ure. Nine women developed mild to moderate acute
GVHD that was treated with a short course of sys-
temic prednisone (Table 1). Seven women developed
mild to moderate GVHD treated with systemic cyclo-
sporine and prednisone during ﬂares according to
standard dosing regimens. Two women had severe
GVHD; these women ultimately died from complica-
tions from the GVHD (Tables 1 and 3).
These patients developed vaginal symptoms on
average 10.2 months (range, 3-24 months) after
HSCT (Table 2). The most common presenting vag-
inal complaints were dryness, itching, and pain to
touch. These symptoms ultimately led to dyspareunia
and the inability to have vaginal intercourse. Although
the symptoms experienced by these women often
closely mimicked those associated with ovarian failure,
the physical features found on pelvic examination
were striking and did not resemble those found during
menopause (either induced or natural).
On physical examination, most patients with mod-
erate vaginal GVHD had narrowing of the vagina,
with thickening of the mucosa and adhesive bands.
The synechiae most commonly either obliterated the
upper vaginal canal or developed circumferentially
around the introitus. At times as the GVHD pro-
gressed, the adhesions foreshortened the vaginal ca-
nal, leading to the inability to visualize the cervix or
perform a Papanicolaou test. Other common ﬁndings
on the vulva and vagina in milder cases were open, ﬂat
sores and erythematous and excoriated mucosa that
was tender and friable to touch. It should be noted
that all cultures of open lesions were negative for
herpes simplex virus. In our series, these mild features
progressed to the more moderate synechiae if patients
did not use the cyclosporine cream on a regular basis.
Although the number of patients was small, after
we reviewed the medical charts, it was clear that the
onset of vulvar or vaginal GVHD did not occur or
worsen with ﬂares in other organ systems, including
skin and oral mucosa. Systemic cyclosporine and ste-
roids did not abate gynecologic ﬁndings except in 1
patient (patient 6). In our series, the severity of vaginal
GVHD also did not correlate with age at the time of
transplantation or the type of HSCT (Table 1). This
is interesting because factors that predict the severity
of chronic GVHD are older age at the time of HSCT,
matched unrelated transplant, and aggressive acute
GVHD [1].
Treatment regimens for the vaginal symptoms ini-
tially included topical estrogens in 6 of the 11 patients.
Topical estrogens were not successful in abating the
symptoms and physical ﬁndings in any of these 6
patients (Table 2). Topical cyclosporine was initiated
in 9 patients before surgical intervention, and 5 of
these patients ultimately required surgery. Two pa-
tients were immediately taken to surgery because of
severe vaginal stenosis (Table 2). Topical cyclosporine
was most successful in treating women with ulcerated
and excoriated tissue on the vulva and vagina. Skin
integrity improved after 2 weeks of cyclosporine. This
topical regimen was also successful in the treatment of
moderate thickening of the vaginal mucosa; its effects
were ameliorated when it was used in concert with
vaginal dilators. Improvements in clinical manifesta-
tions of GVHD were sufﬁcient to avoid surgical in-
terventions in 4 patients.
Surgery was necessary for 7 of the 11 women
(Table 2). After surgery, all patients used topical cy-
closporine with vaginal dilators (Table 3). By 6 to 12
weeks after surgery, these patients were able to resume
vaginal intercourse. In one patient (patient 6), neither
topical cyclosporine nor surgery was able to amelio-
rate her physical ﬁndings or symptoms. Her vaginal
synechiae were thick and dense. Her symptoms ulti-
mately abated with systemic cyclosporine and pred-
Table 3. Pathology and Current Status
Subject
No. Pathology
Postoperative
Cyclosporine Current Status
1 N/A Yes HSIL/VIN, minimal scarring
2 Stromal tissue with chronic inflammation Yes Minimal scarring
3 Lichenoid dermatitis Yes Dead
4 Spongiotic dermatitis N/A HSIL, minimal scarring
5 N/A N/A Dead
6 N/A Yes Resolved with systemic cyclosporine
7 Hyperkeratotic and inflamed epithelium and stroma Yes Minimal scarring
8 Epithelium with inflammation and parakeratosis Yes Minimal scarring
9 N/A N/A Minimal scarring
10 Subacute spongiotic dermatitis N/A Dead
11 Stromal tissue with inflammation Yes Minimal scarring
N/A indicates not available; HSIL, high-grade squamous intraepithelial lesion; VIN, vulvar intraepithelial neoplasm.
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nisone (Table 3). It should be noted that she had
minimal to no GVHD at other sites.
Two of the patients (patients 2 and 7) had almost
complete obstruction of the entire vaginal canal at the
time of presentation, so a trial of topical cyclosporine
was not initiated. These patients were directly taken to
the operating room for surgical lysis of adhesions and
re-creation of the caliber and length of the introitus.
After surgery, these women used topical cyclosporine
and vaginal dilators and resumed sexual activity after 2
months.
Five patients (patients 1, 3, 6, 8, and 11) were
initially started on topical cyclosporine but ultimately
required surgery (Table 2). Patients 3, 6, and 8 did not
complain of any vaginal symptoms until ﬁndings were
severe. In these cases, the synechiae were already
dense and obliterated most of the vaginal canal. Top-
ical cyclosporine was used as a temporizing agent in
these cases to soften the adhesions before surgery. Of
note, patient 3 had been treated with topical estrogens
for longer than 1 year before referral to gynecology.
During this time, her vaginal disease substantially pro-
gressed. Patients 1 and 11 both initially presented with
mild disease and were successfully treated with topical
cyclosporine. Both patients stopped using the cream
when symptoms resolved. These patients did not re-
quire additional therapy until vaginal intercourse was
not possible. Adhesive bands had formed rapidly over
the ensuing months when no topical cyclosporine was
used. At this point, the topical regimen only softened
the synechiae, and the patients required surgical lysis.
It should be noted that the topical cyclosporine had to
be compounded by a pharmacist and was very expen-
sive; it was not always covered by insurance plans.
This may have contributed to lack of patient compli-
ance for long-term use of this medication in these
women.
The pathology of affected vaginal and/or vulvar
mucosa was obtained in 7 women in our series (Table
3). The most common histologic ﬁnding was foci of
chronic and acute inﬂammation within the stroma and
epithelium. Additionally, lichenoid dermatitis (patient
3), spongiotic dermatitis (patients 4 and 10), and hy-
perkeratosis (patients 7 and 8) were observed. These
pathologic ﬁndings were consistent with mucosal and
skin ﬁndings in classic chronic GVHD [11].
Two of the women in our series developed persis-
tent high-grade squamous intraepithelial lesions,
which were detected by Papanicolaou test and con-
ﬁrmed by biopsy and colposcopy (Table 3; patients 1
and 4). Patient 1 underwent large loop excision of the
transformation zone, and all subsequent Papanicolaou
tests have been normal. Patient 4 had persistent high-
grade squamous intraepithelial lesions despite colpos-
copy-guided laser treatment, and she underwent a
total abdominal hysterectomy and bilateral salpingo-
oophorectomy. Final pathology revealed no invasive
cervical disease but did show dysplasia of the vaginal
vault. The dysplasia of the vaginal cuff persisted on
biopsy, and the patient underwent another laser pro-
cedure. Since that time, all Papanicolaou tests have
been within normal limits. All other women in our
series have had normal Papanicolaou tests since the
time of HSCT and topical cyclosporine use.
DISCUSSION
GVHD is a major complication after allogeneic
HSCT; however, involvement of the vagina has not
been well characterized. Vaginal GVHD was ﬁrst de-
scribed in 1982 by Corson et al. [5] in 5 women with
sclerosing vaginitis and stricture formation. Since
then, several cases have been reported with complete
vaginal blockage leading to the formation of hemato-
colpos [6-10]. Vaginal stenosis limits the ability to
perform a routine Papanicolaou test and prevents vag-
inal intercourse. Vulvar excoriations can be painful.
Various treatment regimens have been advocated, in-
cluding topical estrogens, surgical lysis, and vaginal
dilators, with marginal beneﬁt.
This series describes 11 women who developed
GVHD of the vagina and vulva after allogeneic stem
cell transplantation despite receiving systemic cyclo-
sporine and steroids immediately after transplanta-
tion. From our series and other reports of vaginal
stenosis and agglutination, it seems that this form of
chronic GVHD develops on average 10.2 months af-
ter transplantation [5-10], but symptoms can also de-
velop as late as 2 years after the transplantation. In
several of our patients, biopsy samples were obtained
of the affected region. Histologic features were varied
(Table 3), but all revealed patterns similar to those
found on skin affected with chronic GVHD [12]. In
this small series, vaginal GVHD did not occur more
frequently in women who received an HSCT from a
matched unrelated donor than from a sibling-matched
donor (Table 1). It should be noted that the severity of
vaginal and vulvar symptoms did not correlate with
the severity of acute or chronic GVHD found in other
organ systems. Some women with severe vaginal ste-
nosis have only mild chronic GVHD. This is similar
to case reports reported in the literature [5-10].
In our series, all of the women initially received
systemic estrogen therapy at the time of HSCT, and 6
of the patients used topical estrogen for vaginal and
vulvar atrophy. It has been reported that hormone-
replacement therapy does not inﬂuence the severity or
activity of GVHD and can be safely used as a prophy-
lactic measure to treat ovarian failure [13]. The
changes on the vulvar and vaginal mucosa could not
solely be attributed to their hypoestrogenic state. Hy-
poestrogenized vaginal and vulvar mucosa is charac-
terized by thin and atrophic mucosa that responds to
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topical estrogen. The women from our series clearly
had different physical ﬁndings. Synechiae and adhe-
sive bands are never found on examination of meno-
pausal women. Although the vagina may lose some
elasticity, it will not become obliterated with scar
tissue that obscures the cervix. The ﬁndings in our
women, as well as those in case reports [6-10], indicate
that GVHD is a distinct entity from the hypoestro-
genic state of the tissue experienced with ovarian fail-
ure.
In prior studies, women were not treated until the
vagina was completely obliterated, which required
surgical intervention [6-9]. We found that topical cy-
closporine was successful in treatment of vaginal and
vulvar GVHD. This treatment was very successful in
treating the skin changes found on the vulva after
several weeks of application. The response to vaginal
synechiae was varied. When minimal to moderate
scarring was found, cyclosporine cream was successful
in preventing surgery (Table 2). Sometimes these
women required vaginal dilators to help relieve the
symptoms. When women presented with extensive
scarring, partial obstruction of the vagina, and inabil-
ity to visualize the cervix, the cyclosporine cream did
help to soften the scar tissue, but the women required
surgical lysis of the adhesions. After surgery, all
women continued with cyclosporine cream and dila-
tors until they were able to resume vaginal inter-
course. The cyclosporine cream seemed to prevent
any new scarring from developing, and patients con-
tinued to use it as needed. No patient required a
second operation (Table 3).
Several questions arise from this small case series.
First, we do not know the true incidence of vaginal
GVHD. This series was collected in a busy transplan-
tation program over 10 years. During this interval,
501 transplantations were performed in women. It is
possible that many women with vulvovaginal GVHD
did not have symptoms, did not discuss them with the
transplant team, or, possibly, believed that these
symptoms were not a GVHD complication. It is likely
that a number of women are not sexually active after
HSCT, and this may further increase the ascertain-
ment bias.
Second, all the women except 1 in our series had
been receiving systemic cyclosporine while they de-
veloped these symptoms, but there seemed to be sub-
stantial beneﬁt from the additional topical therapy.
Topical cyclosporine has not been effective in skin or
oral mucosal GVHD. This raises the possibility that
the efﬁcacy of topical therapy in the genital region is
due to a presumed prolonged exposure time to the
affected mucosa. The topical cyclosporine was specif-
ically formulated and not commercially available. One
patient (patient 9) did successfully use tacrolimus. It
would be interesting to determine in a larger study
whether tacrolimus is similarly effective. It is possible
that topical cyclosporine may successfully prevent
vaginal adhesions and vulvar skin changes, obviating
the necessity for surgical intervention when applied
early, thus indicating the importance of taking a sexual
history in the posttransplantation period. The women
with the most resistant vaginal GVHD that required
surgery had fairly extensive adhesions at the time of
diagnosis.
Another important question that arises from this
data is as follows: does topical application of immu-
nosuppressive agents such as cyclosporine lead to in-
creased frequency of dysplasia of either the cervix or
vagina? Two women in our series did require treat-
ment for persistent dysplasia. Cyclosporine may make
the vaginal mucosal cells or cervical cells more sus-
ceptible to infection with human papillomavirus,
which may lead to dysplasia. Clearly, a larger series of
women will need to be examined. Of note, in one
retrospective analysis of cervical cytology, women af-
ter allogeneic bone marrow transplantation had
higher rates of cytologic abnormalities (presumably
related to conditioning), and these women may re-
quire more frequent screening [12].
Vulvar and vaginal GVHD seems to be a discrete
entity in the continuum of chronic GVHD. As more
studies are performed, women who experience these
complications can promptly and effectively be treated.
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